Compare TPCS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | CGTX |
|---|---|---|
| Founded | 1956 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 79.6M |
| IPO Year | 2008 | 2021 |
| Metric | TPCS | CGTX |
|---|---|---|
| Price | $5.73 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 59.3K | ★ 382.8K |
| Earning Date | 02-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.38 | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $0.55 |
| 52 Week High | $6.31 | $2.26 |
| Indicator | TPCS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 44.24 |
| Support Level | $4.41 | $0.93 |
| Resistance Level | $5.69 | $1.18 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 65.30 | 16.33 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).